Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

19.36 +0.09 (+0.49%)

Delayed Quote Updated: 9:48 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

April 05, 2024

From Legend Biotech Corporation

Via Business Wire

Unveiling 9 Analyst Insights On Legend Biotech ↗

April 01, 2024

Via Benzinga

GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy ↗

March 20, 2024

Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual...

Via Benzinga

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

March 19, 2024

From Legend Biotech Corporation

Via Business Wire

Earnings Preview: Legend Biotech ↗

March 08, 2024

Via Benzinga

What 4 Analyst Ratings Have To Say About Legend Biotech ↗

March 07, 2024

Via Benzinga

Key Takeaways From Legend Biotech Analyst Ratings ↗

December 19, 2023

Via Benzinga

FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer ↗

March 18, 2024

FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &...

Via Benzinga

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

March 15, 2024

From Legend Biotech Corporation

Via Business Wire

FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers ↗

March 13, 2024

Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into...

Via Benzinga

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

March 13, 2024

U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.

Via Benzinga

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

March 11, 2024

From Legend Biotech Corporation

Via Business Wire

Earnings Scheduled For March 11, 2024 ↗

March 11, 2024

Companies Reporting Before The Bell • Ballard Power Systems (NASDAQ:BLDP) is estimated to report quarterly loss at $0.13 per share on revenue of $34.20 million.

Via Benzinga

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗

March 09, 2024

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...

Via Talk Markets

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗

March 07, 2024

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.

Via Benzinga

Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership ↗

February 24, 2024

Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody...

Via Talk Markets

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

February 23, 2024

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

February 13, 2024

From Legend Biotech Corporation

Via Business Wire

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗

January 23, 2024

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.

Via Benzinga

As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks? ↗

January 10, 2024

Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments.

Via Benzinga

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗

January 04, 2024

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...

Via Benzinga

Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

January 03, 2024

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Legend Biotech Corporation

Via Business Wire

Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗

December 29, 2023

Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.

Via Benzinga

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

December 11, 2023

From Legend Biotech Corporation

Via Business Wire

Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say ↗

December 11, 2023

Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or

Via Benzinga

Earnings Scheduled For November 20, 2023 ↗

November 20, 2023

Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million.

Via Benzinga

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

November 20, 2023

From Legend Biotech Corporation

Via Business Wire

Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗

November 18, 2023

Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...

Via Talk Markets

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On ↗

November 16, 2023

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.